Group 1 - The National Healthcare Security Administration (NHSA) has released a guideline for pricing surgical and treatment auxiliary operations, which aims to address the commercialization bottleneck of surgical robots by establishing a differentiated pricing mechanism based on clinical value and participation level [1] - The guideline categorizes pricing for robotic-assisted surgeries into three tiers: navigation, participation in execution, and precise execution, with higher fees for robots that demonstrate greater involvement and functionality [1] - The NHSA will guide local authorities in setting reasonable pricing standards to ensure clinical accessibility while enhancing pricing regulation [1] Group 2 - A new pricing item for "remote surgical assistance" has been established to facilitate the application of remote surgery, allowing medical institutions to charge for remote control of surgical instruments [2] - This pricing initiative aims to bridge the gap between clinical exploration and practical application of remote surgery, promoting the expansion of quality medical resources across regions and enhancing accessibility [2] - The introduction of remote surgery is expected to drive technological innovations in related fields, leading to advancements in surgical robots, navigation devices, and monitoring equipment [2] Group 3 - The guideline clarifies the charging policies for reusable and disposable consumables, stating that only one type of charge can be applied at a time [3] - If disposable consumables are used, they will be sold at zero markup, and no auxiliary operation fees will be charged; if reusable consumables are used, the corresponding auxiliary operation fees will be charged [3] - This regulation aims to suppress unreasonable pricing behaviors and promote more transparent clinical charging practices [3] Group 4 - The guideline includes a "data reduction" policy for medical data storage and upload, which will be part of the pricing structure [4] - Medical institutions must store and upload required medical data and device operation records; failure to do so will result in reduced charges [4] - Analyzing extensive and continuous data on device performance and clinical outcomes will help build a scientific evaluation model for efficacy and benefits, facilitating the optimization of technology applications and the development of new surgical techniques [4]

Core Insights - The National Healthcare Security Administration has released a guideline for pricing surgical and treatment auxiliary operations, focusing on advanced medical technologies such as 3D printing and robotic surgery [1][2] Group 1: Pricing Structure - The guideline establishes 37 pricing projects, 5 additional charges, and 1 expansion item, standardizing the pricing for robotic-assisted surgeries based on clinical value and participation levels [1] - A tiered pricing model is introduced for robotic surgeries, with higher fees for robots that are more involved and precise in surgical execution [1] - The guideline aims to ensure reasonable pricing standards across regions while enhancing the accessibility of robotic-assisted surgeries [1] Group 2: Remote Surgery - A new pricing project for "remote surgical assistance" has been established, facilitating the application of remote surgery in clinical settings [2] - This pricing structure allows medical institutions to charge for remote control of surgical instruments, promoting the expansion of quality medical resources across regions [2] - The implementation of remote surgery is expected to drive technological innovations in surgical robotics and navigation devices [2] Group 3: Consumables and Charges - The guideline clarifies the charging policies for reusable and disposable consumables, stating that they cannot be charged simultaneously [2] - Institutions using disposable consumables will sell them at zero markup, while those using reusable consumables will charge for auxiliary operation fees [2] - This regulation aims to curb unreasonable price increases and promote transparency in clinical charges [2] Group 4: Data and Future Applications - The guideline includes a "data reduction policy," where medical data storage and upload are part of the pricing structure [3] - Institutions must provide required data to avoid penalties, enabling the development of effective evaluation models for treatment efficacy [3] - This approach is expected to accelerate the development of new surgical techniques and expand applications in telemedicine and smart navigation [3] Investment Opportunities - The new policy is anticipated to resolve previous pricing ambiguities for surgical robots, emphasizing clinical value and participation levels [3] - Companies with technological advancements and product maturity, such as Tianzhihang-U, Jingfeng Medical-B, and others, are likely to benefit from the inclusion of robotic-assisted surgery in healthcare directories [3]

Core Insights - The National Healthcare Security Administration (NHSA) released a guideline focusing on pricing for surgical and treatment auxiliary operations, emphasizing advanced medical technologies such as 3D printing and robotic surgery [1][2] Group 1: Pricing Guidelines - The guideline establishes 37 pricing items, 5 additional charges, and 1 expansion item, aiming to standardize pricing for innovative medical technologies [1] - Pricing is categorized based on the level of robotic participation in surgeries, with three tiers: navigation, participation, and precision execution, promoting the use of advanced surgical robots in complex procedures [1][2] Group 2: Impact on Healthcare - The pricing initiative is expected to facilitate the transition of remote surgeries from experimental stages to practical applications, benefiting patients, healthcare institutions, and pharmaceutical companies [2] - The guideline aims to enhance the accessibility of quality medical resources across regions and innovate the hierarchical diagnosis and treatment model [2] Group 3: Cost Considerations - The guideline specifies that auxiliary operation fees should reflect the clinical value and usage costs of consumables, prohibiting simultaneous charges for disposable materials and corresponding auxiliary operation fees [2] - To ensure quality control and traceability in robotic and remote surgeries, the guideline includes requirements for storing and uploading medical data and equipment operation records, with penalties for non-compliance [2]

Group 1 - The core viewpoint of the news highlights the growth of the biomedical sector in China's STAR Market, with the STAR Market Biomedical Index rising by 0.29% and specific stocks like Tianzhihang increasing by 14.64% [1] - The National Healthcare Security Administration has released a guideline for pricing surgical and treatment auxiliary medical services, establishing a fee framework for innovative technologies such as surgical robots and remote surgeries, promoting a coefficient-based charging model linked to robotic assistance [1] - Guohai Securities points out that artificial intelligence is accelerating the empowerment of the entire pharmaceutical industry chain, with NVIDIA and Eli Lilly announcing a joint AI innovation lab, investing up to $1 billion over five years to explore AI applications in drug discovery, development, and manufacturing [1] Group 2 - As of December 31, 2025, the top ten weighted stocks in the STAR Market Biomedical Index include companies like United Imaging Healthcare and BeiGene, collectively accounting for 48.85% of the index [1] - The STAR Market Medical ETF by Harvest (588700) closely tracks the STAR Market Biomedical Index, providing an easy investment opportunity in the biomedical sector for investors without stock accounts through the Harvest Medical ETF linked fund (021061) [2]

Core Insights - The National Healthcare Security Administration (NHSA) has released a guideline to standardize pricing for surgical robots and other innovative medical technologies, addressing the inconsistency in medical service charges across China [1][2] Group 1: Pricing Guidelines for Surgical Technologies - The NHSA's guideline categorizes pricing into three tiers based on the level of surgical robot involvement: navigation, participation, and precision execution [2][3] - A new "remote surgery assistance fee" has been established, allowing experts in resource-rich areas to charge for remote surgeries conducted for patients in other regions [3][4] - The guideline aims to ensure that medical institutions maintain and upload operational data and records, with penalties for non-compliance to ensure quality control [1] Group 2: Market Trends and Innovations - The market share of domestic surgical robots in China has increased from 32.61% in 2023 to 48.89% in 2024, indicating significant advancements in domestic technology [3] - Despite the growth, the participation rate of robots in surgeries in China is only 6.33%, compared to 42% in the United States, highlighting the potential for further utilization of robotic technology in surgical procedures [3] Group 3: Pathology Pricing Guidelines - The NHSA has also established a pricing guideline for pathology services, including 28 pricing items and 3 additional charges, covering the entire process from sampling to diagnosis [6] - The pathology guideline emphasizes the value of technical labor and aims to support the integration of AI in pathology, enhancing data foundations for future applications [6]

Core Viewpoint - Shenzhen Precision Medical Technology Co., Ltd. (referred to as Precision Medical) successfully listed on the Hong Kong Stock Exchange on January 8, 2026, with a market capitalization of HKD 22.507 billion and a stock price increase of over 30% on the first day of trading [1][3]. Company Overview - Founded by a couple of PhD graduates in 2017 with an initial capital of CNY 100,000, Precision Medical has grown to a valuation exceeding CNY 10 billion in less than nine years [3][5]. - The company has three approved products, including the multi-port laparoscopic surgical robot, which has been registered for use in various surgical fields and has signed sales agreements for 61 units globally [3][9]. Financial Performance - Precision Medical has reported significant losses, with cumulative losses exceeding CNY 1.1 billion since 2020. The company’s revenues for 2023, 2024, and the first half of 2025 were CNY 48.042 million, CNY 160 million, and CNY 149 million, respectively, while net losses were CNY 213 million, CNY 219 million, and CNY 89.087 million [10][11]. Market Position and Competition - The surgical robot market in China is projected to exceed CNY 100 billion by 2033, with the laparoscopic surgical robot segment being the largest [9]. - Precision Medical faces intense competition, with over 10 similar products already approved in the market, including the well-established Da Vinci system, which has begun local production, thereby increasing competitive pressure on domestic manufacturers [11][12]. Product Development and Strategy - The company has developed a "shared platform" design allowing its multi-port and single-port laparoscopic robots to share the same control console, aiming to reduce costs for hospitals and enhance operational efficiency [12][13]. - Precision Medical is also expanding its training centers globally and has received CE certification for its products, indicating a focus on international market expansion and advanced applications like remote surgery [13].

Core Insights - Weijing Medical has completed a B+ round financing of over 100 million yuan, with exclusive investment from Guotai Junan Innovation Investment Co., Ltd. and additional investment from strategic shareholder Kangji Medical [2][3] Funding Utilization - The raised funds will primarily accelerate the commercialization of products and promote the research and clinical registration of next-generation products [3] Technological Advancements - Weijing Medical has developed a competitive product matrix addressing clinical pain points in surgery, achieving significant breakthroughs in technology [4] - Optimization of control systems has led to lightweight and smooth operations, addressing core challenges in motion compensation and gap control [4] - System performance has improved with overall latency controlled within 80 milliseconds, and video systems achieving 4K fluorescence signal capture and transmission within 40 milliseconds [4] - The surgical experience has been enhanced with dual 4K display and image transmission latency below 55 milliseconds, providing immersive high-definition surgical vision [4] Innovation in Surgical Navigation - The company is focusing on embodied intelligence, particularly in remote surgery and AI navigation, developing innovative solutions that meet clinical needs [4] - The intraoperative navigation system can identify and alert surgeons to key anatomical structures, aiding in precise surgical planning and enhancing safety and operational accuracy [4] Product Registration and Clinical Application - Weijing Medical's core product, the four-arm laparoscopic surgical robot, received its registration certificate in April 2025, marking a new phase for domestic surgical robots in large-scale clinical applications [5] - The Weijing robot is currently in trial use at over 10 top hospitals across China, including Peking University Third Hospital and Shanghai Changzheng Hospital [5]

深圳市精鋒醫療科技股份有限公司 Shenzhen Edge Medical Co., Ltd. 股份代號 : 2675 （於中華人民共和國註冊成立的股份有限公司） 全球發售 聯席保薦人、整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 重要提示 重要提示： 閣下如對本文件的任何內容有任何疑問，應尋求獨立專業意見。 Shenzhen Edge Medical Co., Ltd. 深圳市精鋒醫療科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 全球發售 | 全球發售項下的發售股份數目 | ： | 27,722,200股H股（視乎超額配股權行使 | | --- | --- | --- | | 與否而定） | | | | 香港發售股份數目 | ： | 2,772,300股H股（可予重新分配） | | 國際發售股份數目 | ： | 24,949,900股H股（可予重新分配及視乎 | | 超額配股權行使與否而定） | | | | 發售價 | ： | 每股H股43.24港元，另加1.0%經紀 | ...

Group 1 - The core viewpoint of the news is that Hangzhou Kangji Weijing Medical Robotics Co., Ltd. has completed a B+ round financing of over 100 million yuan, with the funds aimed at accelerating product commercialization and developing new generation products and functions [1] - The financing was exclusively invested by Guotai Junan Innovation Investment Co., Ltd., with strategic shareholder Kangji Medical also increasing its investment, and Gelu Capital serving as the exclusive financial advisor for the transaction [1] - The core team of Weijing Medical originates from the National Key Laboratory of Robotics Technology and Systems at Harbin Institute of Technology, having applied for over 400 patents over the past 20 years [1] Group 2 - Weijing Medical's core product, the four-arm laparoscopic surgical robot, received its registration certificate in April 2025, marking a new phase of large-scale clinical application for domestic surgical robots [2] - Clinical data indicates that there have been no cases requiring conversion to traditional open surgery, demonstrating the system's outstanding stability, safety, and effectiveness in handling complex anatomical structures and high-difficulty surgeries [2]

Core Viewpoint - The article highlights the successful commercialization and global expansion of the TUMAI® robotic surgical system, marking a significant milestone in China's medical technology innovation and its role in global healthcare [2][4]. Group 1: Commercialization Milestones - The TUMAI® robotic surgical system has officially landed in Brazil at Hospital Unimed Foz do Iguaçu, marking the 100th commercial installation globally, with over 160 cumulative orders to date [2][10]. - The rapid growth in orders from October to December 2025, from over 100 to 160+, showcases the unprecedented commercialization speed of the TUMAI® system [10]. - The TUMAI® robot has achieved a significant market presence, becoming the first domestic laparoscopic surgical robot to reach 100 commercial installations, indicating its reliability and clinical stability [2][10]. Group 2: Strategic Partnerships and Market Integration - Hospital Unimed Foz do Iguaçu represents a key part of Brazil's Unimed healthcare system, the largest cooperative healthcare system in Brazil, indicating TUMAI®'s deep integration capabilities within established healthcare frameworks [8]. - The successful installation at this flagship hospital demonstrates TUMAI®'s ability to align with procurement models, maintenance costs, and training systems, enhancing its market expansion potential in Brazil and Latin America [8][10]. - The TUMAI® robot's entry into various international markets, including partnerships with top medical institutions in countries like Belgium, Italy, and India, reflects its growing global footprint and acceptance [25][29]. Group 3: Ecosystem Development and Technological Advancements - A multi-layered robotic surgical ecosystem is forming, integrating top experts, regional medical centers, and grassroots hospitals, facilitating the widespread adoption of robotic surgery [32]. - The TUMAI® system has enabled remote surgical capabilities across various regions, including successful cross-border surgeries in the Middle East and Europe, enhancing the accessibility of high-quality surgical resources [34][41]. - The article emphasizes the importance of TUMAI®'s technological advancements and its ability to adapt to diverse regulatory and clinical environments, establishing a competitive edge in the global market [42].